BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
EYLEA HD (aflibercept) by Regeneron is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2023.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EYLEA HD (aflibercept) is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF), approved in August 2023 for retinal diseases including diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion. It works by binding and neutralizing VEGF to reduce abnormal blood vessel growth and fluid accumulation in the retina. The HD formulation represents an enhanced delivery platform from Regeneron's established EYLEA franchise.
$0.656MPart D
GrowthGrowing
Early-stage growth product with expanding label penetration and increasing manufacturing demand; growing cross-functional teams support market expansion.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
Started Dec 2026
50 enrolled
Polypoidal Choroidal VasculopathyPolypoidal Choroidal Vasculopathy (PCV)
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema
Started Apr 2026
256 enrolled
Diabetic Macular Edema
A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration
Started Mar 2026
356 enrolled
Neovascular Age-Related Macular Degeneration (nAMD)
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
Started Jan 2026
174 enrolled
Polypoidal Choroidal Vasculopathy (PCV)Neovascular Age Related Macular Degeneration (AMD)
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
Started Aug 2025
180 enrolled
Wet Age-related Macular Degeneration (wAMD)
Worked on EYLEA HD at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.